Biotest AG, DE0005227235

Biotest AG, DE0005227235

14.11.2022 - 09:33:22

EQS-News: Biotest AG: Biotest receives approval for new intravenous immunoglobulin Yimmugo?

14.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at www.eqs-news.com

Language: English Company: Biotest AG Landsteinerstra?e 5 63303 Dreieich

Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: ir@biotest.com Internet: www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1486621 ? End of News EQS News Service

1486621??14.11.2022?CET/CEST

@ dgap.de